Skip to main content

Refine your results

Filters
Date
Displaying 1101 - 1120 of 3968

Statement of the Federal Trade Commission in the matter of Roche Holding/Spark Therapeutics

In the matter of Roche Holding/Spark Therapeutics
Date
Matter Number

191 0086

By
Joseph J. Simons, Former Chairman;
Noah Joshua Phillips, Former Commissioner;
Rohit Chopra, Former Commissioner;
Rebecca Kelly Slaughter, Former Commissioner;
Christine S. Wilson, Former Commissioner
Related Releases
Federal Trade Commission Closes Investigation of Roche Holding AG’s Proposed Acquisition of Spark Therapeutics, Inc.

Statement of the Federal Trade Commission in the matter of Roche Holding/Spark Therapeutics

In the matter of Roche Holding/Spark Therapeutics
Date
Matter Number

191 0086

By
Joseph J. Simons, Former Chairman;
Noah Joshua Phillips, Former Commissioner;
Rohit Chopra, Former Commissioner;
Rebecca Kelly Slaughter, Former Commissioner;
Christine S. Wilson, Former Commissioner
Related Releases
Federal Trade Commission Closes Investigation of Roche Holding AG’s Proposed Acquisition of Spark Therapeutics, Inc.

Statement of the Federal Trade Commission in the matter of Roche Holding/Spark Therapeutics

In the matter of Roche Holding/Spark Therapeutics
Date
Matter Number

191 0086

By
Joseph J. Simons, Former Chairman;
Noah Joshua Phillips, Former Commissioner;
Rohit Chopra, Former Commissioner;
Rebecca Kelly Slaughter, Former Commissioner;
Christine S. Wilson, Former Commissioner
Related Releases
Federal Trade Commission Closes Investigation of Roche Holding AG’s Proposed Acquisition of Spark Therapeutics, Inc.

Statement of the Federal Trade Commission in the matter of Roche Holding/Spark Therapeutics

In the matter of Roche Holding/Spark Therapeutics
Date
Matter Number

191 0086

By
Joseph J. Simons, Former Chairman;
Noah Joshua Phillips, Former Commissioner;
Rohit Chopra, Former Commissioner;
Rebecca Kelly Slaughter, Former Commissioner;
Christine S. Wilson, Former Commissioner
Related Releases
Federal Trade Commission Closes Investigation of Roche Holding AG’s Proposed Acquisition of Spark Therapeutics, Inc.

Statement of the Federal Trade Commission in the matter of Roche Holding/Spark Therapeutics

In the matter of Roche Holding/Spark Therapeutics
Date
Matter Number

191 0086

By
Joseph J. Simons, Former Chairman;
Noah Joshua Phillips, Former Commissioner;
Rohit Chopra, Former Commissioner;
Rebecca Kelly Slaughter, Former Commissioner;
Christine S. Wilson, Former Commissioner
Related Releases
Federal Trade Commission Closes Investigation of Roche Holding AG’s Proposed Acquisition of Spark Therapeutics, Inc.

Concurring Statement of Commissioner Rebecca Kelly Slaughter In the Matter of the University of Phoenix, Inc.

Washington, D.C.
Date
Matter Number

152 3231

By
Rebecca Kelly Slaughter, Former Commissioner
Related Releases
FTC Obtains Record $191 Million Settlement from University of Phoenix to Resolve FTC Charges It Used Deceptive Advertising to Attract Prospective Students

Dissenting Statement of Commissioner Rohit Chopra In the Matter of Bristol-Myers Squibb Company and Celgene Corporation

Washington, D.C.
Date
Matter Number

191 0061

Docket Number
C-4690
By
Rohit Chopra, Former Commissioner
Related Releases
FTC Requires Bristol-Myers Squibb Company and Celgene Corporation to Divest Psoriasis Drug Otezla as a Condition of Acquisition
FTC Approves Modifications to Bristol Meyers Squibb Divestiture Agreement

Statement of Commissioner Christine S. Wilson In the Matter of Bristol-Myers Squibb Company and Celgene Corporation

Washington, D.C.
Date
Matter Number

191 0061

Docket Number
C-4690
By
Christine S. Wilson, Former Commissioner
Related Releases
FTC Requires Bristol-Myers Squibb Company and Celgene Corporation to Divest Psoriasis Drug Otezla as a Condition of Acquisition
FTC Approves Modifications to Bristol Meyers Squibb Divestiture Agreement

Statement of Commissioner Noah Joshua Phillips In the Matter of Bristol-Myers Squibb Company and Celgene Corporation

Washington, D.C.
Date
Matter Number

191 0061

Docket Number
C-4690
By
Noah Joshua Phillips, Former Commissioner
Related Releases
FTC Requires Bristol-Myers Squibb Company and Celgene Corporation to Divest Psoriasis Drug Otezla as a Condition of Acquisition
FTC Approves Modifications to Bristol Meyers Squibb Divestiture Agreement

Dissenting Statement of Commissioner Rebecca Kelly Slaughter In the Matter of Bristol-Myers Squibb Company and Celgene Corporation

Washington, D.C.
Date
Matter Number

191 0061

Docket Number
C-4690
By
Rebecca Kelly Slaughter, Former Commissioner
Related Releases
FTC Requires Bristol-Myers Squibb Company and Celgene Corporation to Divest Psoriasis Drug Otezla as a Condition of Acquisition
FTC Approves Modifications to Bristol Meyers Squibb Divestiture Agreement

Prepared Statement of the Federal Trade Commission Before the House Judiciary, Subcommittee on Antitrust, Commercial, and Administrative Law: “Hearing on Online Platforms and Market Power, Part 4: Perspectives of the Antitrust Agencies"

Before the House Judiciary, Subcommittee on Antitrust, Commercial, and Administrative Law
Washington, DC
Congressional Session
116th Congress
Date
Matter Number

P180101

By
Joseph J. Simons, Former Chairman
Related Releases
FTC Testifies before House Judiciary Subcommittee On Competition Enforcement and Policy, Including in Technology Markets
Displaying 1101 - 1120 of 3968

Join us at the FTC!

View our open positions

Return to top